Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow IMA by emailGet an email when IMA pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about IMA, unsubscribe in one click. Privacy
📣 What IMA Says Is Next
in 2028 · “Initial data expected in 2028, leveraging the clinical operations and investigator network the Company has developed through its atopic dermatitis program.”
Company press release, Aug 5, 2026 · SEC filing
in 2026 · “Alopecia Areata : Imagene remains on track to initiate a Phase 2 study of olevaprubart in alopecia areata in 2026.”
Company press release, Aug 5, 2026 · SEC filing
fourth quarter of 2027 · “Topline data from the study is anticipated in the fourth quarter of 2027.”
Company press release, Aug 5, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full IMA picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for IMA and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.